Watchlist

Watchlist
Aimmune Therapeutics, Inc. (AIMT)
Aimmune Therapeutics, Inc. (AIMT)
Your Daily Pharma Scoop: Right Time To Buy Regeneron, Eli Lilly Gives Guidance, Bluebird Announces Offering
Content Analysis of coverage: REGN Stocks in the news: LLY, SNY, BLUE Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Trade Idea of the Day (for TPT subscribers only) Subscriber Questions & An…
Your Daily Pharma Scoop: Gilead's Potential, Celgene CAR-T Candidate, Cellectar Soars
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day ea…
Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Chief Financial Officer Eric Bjerkholt will participate in a fireside chat at the BMO Capital Markets 2017 Prescriptions for Success Healthca…
Aimmune Therapeutics: Upside Into Q1 Data And Beyond
Shares of Aimmune Therapeutics (AIMT) have risen by 75% since my late February article, where I called the stock a "solid Runner of the Year candidate." AIMT data by YCharts Keys to the original bullish thesis included the following: I was optimistic on oral biologic drug candidate…
Aimmune Therapeutics (AIMT) On Peanut Allergy Treatment - Slideshow
The following slide deck was published by Aimmune Therapeutics in conjunction with this Read more …
Medical Stocks: Investing For 2018
2017 has turned out to be a good year for medical stocks, with strong gains in biopharmaceuticals, medical devices, diagnostics and HMOs. This can be attributed to a strong overall stock market, a quieting of concerns regarding drug pricing, an unchanged ACA and an underlying 6% growth rate …
Peanut Wars: Things Are Heating Up Between Aimmune Therapeutics And DBV Technologies
( Source ) AIMT data by YCharts Intro Hello, readers. Earlier in the year, I wrote an article that compared and contrasted DBV Technologies (DBVT) and Aimmune Therapeutics (AIMT). I stated that Aimmune Therapeutics was my preferred play, that I am long the name, and t…
Update On Aimmune Therapeutics Vs. DBV Technologies Peanut Allergy-Related Candidate Treatments
Updated Investment Thesis: We previously published a Seeking Alpha article where we concluded that although Aimmune Therapeutics (AIMT) appeared to have a more efficacious treatment for preventing severe anaphylaxis upon accidental exposure to peanuts, both AIMT and DBV Technologies (DBVT)…
Premarket analyst action - healthcare
Aethlon Medical (NASDAQ: AEMD ) initiated with Buy rating and $3 (209% upside) price target by H.C. Wainwright. More news on: Aethlon Medical, Inc., Aimmune Therapeutics, Ablynx NV, Healthcare stocks news, Read more …
Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 1, 2017. The event will bring together leading expert allergists to discuss t…
Aimmune Therapeutics (AIMT) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
The following slide deck was published by Aimmune Therapeutics in conjunction with this Read more …
Aimmune Therapeutics, Inc. (AIMT)